KALA BIO (KALA) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
3 Nov, 2026Opening remarks and agenda
Meeting called to order after confirmation of a quorum; five agenda items were presented, and polls opened for electronic voting.
Proxy materials were made available on September 24, 2026, to stockholders of record as of September 10, 2026.
Board and executive committee updates
Yonatan Colman and Brendan Purdy were nominated as Class III directors, with terms running until the 2029 annual meeting if elected.
Shareholder proposals
Proposals sought approval of executive compensation on a non-binding advisory basis, ratification of HTL International, LLC as auditor for FY ended December 31, 2026, and authorization for a 1-for-2 to 1-for-300 reverse stock split at the board’s discretion.
A fifth proposal sought authority to adjourn or postpone the meeting if needed to continue soliciting votes; the board recommended support if necessary.
Latest events from KALA BIO
- Stockholders will vote on director elections, executive pay, auditor ratification, and a reverse stock split.KALA
Proxy filing - Stockholders will vote on director elections, compensation, auditor, and a reverse stock split.KALA
Proxy filing - Net loss narrowed sharply as focus shifted to AI platform, with liquidity supported by note receivable.KALA
Q2 2026 - Pivoting to AI platform services for biotech, with $350M shelf registration and recent restructuring.KALA
Registration filing - Q1 2026 net loss fell to $1.6M as focus shifted to AI platform and cost reductions.KALA
Q1 2026 - Pivoting to AI for biotech, offering $350M in securities amid high strategic and execution risk.KALA
Registration filing - Transitioned to AI platform development after clinical failure, with narrowed losses and ongoing liquidity risks.KALA
Q4 2025 - Registering 241M+ shares for resale amid Nasdaq compliance risks and leadership changes.KALA
Registration Filing - KPI-012's phase II-B trial for PCED targets a major unmet need, with data expected Q1 2025.KALA
H.C. Wainwright 4th Annual Ophthalmology Virtual Conference